Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NETANYA, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (the “Company”) today announced that on March 25, 2026, the Company received a notice from the staff of NYSE...
-
Miami, Florida, March 27, 2026 (GLOBE NEWSWIRE) -- The Arm Confidence Problem That Nobody Talks About There is a conversation happening in dressing rooms, group chats, and doctors' offices...
-
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with...
-
Vera Therapeutics announces inducement grants Under Nasdaq Listing Rule 5635(c)(4).
-
Ghent, 27 March 2026 – 18:30 – Press release / regulated information – inside information ABO-Group Environment achieves its revenue target with double-digit growth in 2025. Highlights 2025 With...
-
BENSALEM, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
-
WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative...
-
LOS ANGELES, March 27, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
-
NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for...
-
Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Bispecific T-Cell Engagers Market Report 2026" has been added to ResearchAndMarkets.com's offering. The bispecific T-cell engagers market is...